4/3/23 – RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation April 3, 2023j3ff1 Read More
3/28/23 – RespireRx Pharmaceuticals Inc. Announces the Appointment of Joseph Siegelbaum as an Independent Member of the Board of Directors March 28, 2023j3ff1 Read More
3/1/23 – ResolutionRx Ltd and RespireRx Pharmaceuticals Inc. Announce ResolutionRx’s Entry into a Services Agreement with iNGENu CRO Pty Ltd March 1, 2023j3ff1 Read More
2/1/23 – ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits February 1, 2023j3ff1 Read More
1/23/23 – RespireRx Pharmaceuticals Inc. Announces the 2nd Amendment to its License Agreement with the University of Illinois January 23, 2023j3ff1 Read More
1/12/23 – RespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid Platform January 23, 2023j3ff1 Read More
12/5/22 – RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development December 5, 2022j3ff1 Read More
11/17/22 – RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Sleep Apnea November 17, 2022j3ff1 Read More
11/10/22 – RespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4 November 10, 2022j3ff1 Read More
11/7/22 – RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa is an Invited Speaker at the 5th Meridian Drug Discovery Summit November 8, 2022j3ff1 Read More
